Clear answers for an investigational field
The terms research, IND, clinical trial, and FDA approval have different meanings. These answers keep those boundaries visible.
Research and clinical status
Does Axiom offer stem-cell treatment to patients?
No treatment or individual medical advice is offered through this website. The disease-area content describes investigational research and development planning for professional organizations.
Are cell therapies approved for COPD, lupus, or kidney injury in the United States?
As of end of 2025, there are no FDA licensed cell-based products approved for these three indications. Regulatory status can change and must be checked against current FDA records.
Does a ClinicalTrials.gov listing mean FDA approved the therapy?
No. Registry listing does not establish that FDA reviewed the study, authorized marketing, or determined that the product is safe or effective.
Does filing an IND mean a product is FDA approved?
No. An IND is the pathway for studying an investigational product in humans under applicable requirements. Submission, an IND becoming effective, trial completion, and marketing approval are separate milestones.
Development support
How can Axiom support an IND program?
Support can include product and indication framing, CMC gap assessment, potency strategy, nonclinical planning, clinical protocol concepts, FDA meeting preparation, submission workstream organization, document review, and project governance. The exact scope must be defined in writing.
Can Axiom guarantee FDA agreement or IND clearance?
No. FDA decisions depend on the exact product, evidence, proposed study, sponsor responsibilities, and current regulatory requirements. No adviser can responsibly guarantee the outcome.
Are MSC, hematopoietic stem-cell transplant, CAR-T, NK cells, and extracellular vesicles the same pathway?
No. They differ in composition, mechanism, manufacturing, persistence, risk, clinical use, and regulatory questions. Each requires a product-specific analysis.
Do you provide materials for human administration?
This website does not make a general clinical-supply claim. Any human-use engagement would require product-specific scope, applicable authorization, manufacturing and quality evidence, contracts, and independent regulatory review.
Training and quality systems
Can training be tailored to our process?
Yes, after a scoped review of roles, procedures, equipment, quality requirements, risks, and competency goals. Proprietary information should be exchanged only under an appropriate confidentiality and security process.
Does training certify a facility for GMP manufacturing?
No. Training is one element of readiness. Facility design, qualification, procedures, quality oversight, personnel qualification, product controls, inspections, licenses, and regulatory authorization remain separate requirements.
Engagement
How does a project begin?
A focused scoping discussion should establish the product, indication, modality, stage, evidence available, decisions needed, stakeholders, confidentiality needs, timeline, and deliverables. A written scope should follow before technical work starts.
Can we send patient records or confidential CMC details through the contact form?
No. The form opens your email application and is intended only for a high-level inquiry. Do not include patient data, protected health information, trade secrets, unpublished protocols, credentials, or controlled documents.